NASDAQ:ANAB AnaptysBio (ANAB) Stock Price, News & Analysis $55.67 -1.35 (-2.37%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$55.71 +0.04 (+0.07%) As of 05/29/2026 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About AnaptysBio Stock (NASDAQ:ANAB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AnaptysBio alerts:Sign Up Key Stats Today's Range$54.87▼$57.3850-Day Range$50.95▼$70.2252-Week Range$11.40▼$72.36Volume502,081 shsAverage Volume566,664 shsMarket Capitalization$1.62 billionP/E RatioN/ADividend YieldN/APrice Target$79.18Consensus RatingModerate Buy Company Overview AnaptysBio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions. The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders. Among its leading candidates is ANB020, an anti-IL-33 antibody being evaluated for atopic dermatitis and eosinophilic asthma, and ANB019, an anti-IL-36 receptor antibody in development for generalized pustular psoriasis. In addition to its clinical assets, AnaptysBio is advancing several preclinical programs aimed at novel immuno-oncology targets, reflecting its commitment to broadening the therapeutic potential of its platform. AnaptysBio has established strategic partnerships to enhance its research and development efforts. These collaborations include agreements with major pharmaceutical companies to co-develop and commercialize select antibody candidates. Through these alliances, AnaptysBio gains access to expanded development expertise, global regulatory capabilities, and commercialization support, while retaining rights to key programs emerging from its discovery engine. Since completing its initial public offering in 2016, AnaptysBio has grown its team and infrastructure to support both early-stage discovery and late-stage clinical development. The company is led by President and Chief Executive Officer Hamza Suria and maintains research operations in the United States. AnaptysBio’s mission is to deliver differentiated antibody therapeutics that address unmet medical needs in inflammatory diseases and cancer.AI Generated. May Contain Errors. Read More AnaptysBio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreANAB MarketRank™: AnaptysBio scored higher than 60% of companies evaluated by MarketBeat, and ranked 342nd out of 870 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAnaptysBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 1 strong buy rating, 10 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAnaptysBio has a consensus price target of $79.18, representing about 42.2% upside from its current price of $55.67.Amount of Analyst CoverageAnaptysBio has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AnaptysBio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AnaptysBio are expected to grow in the coming year, from ($1.15) to $3.47 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AnaptysBio is -51.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AnaptysBio is -51.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnaptysBio has a P/B Ratio of 126.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AnaptysBio's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.78% of the float of AnaptysBio has been sold short.Short Interest Ratio / Days to CoverAnaptysBio has a short interest ratio ("days to cover") of 7.26.Change versus previous monthShort interest in AnaptysBio has recently increased by 7.50%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnaptysBio does not currently pay a dividend.Dividend GrowthAnaptysBio does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment0.88 News SentimentAnaptysBio has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for AnaptysBio this week, compared to 6 articles on an average week.Search Interest6 people have searched for ANAB on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added AnaptysBio to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AnaptysBio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,247,594.00 in company stock.Percentage Held by Insiders33.50% of the stock of AnaptysBio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsAnaptysBio has minimal institutional ownership at this time.Read more about AnaptysBio's insider trading history. Receive ANAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANAB Stock News HeadlinesAnaptysBio Details Tax Treatment of Spin-Off DividendMay 29 at 5:50 PM | tipranks.comJ.P. Morgan Sticks to Its Buy Rating for AnaptysBio (ANAB)May 25, 2026 | theglobeandmail.comHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in before the IPO. Jeff Brown, who identified Bitcoin, Tesla, and Nvidia before gains as high as 52,400%, 2,150%, and 32,000% respectively, is sharing the details on how to claim a stake in Elon Musk's company before it hits public markets.May 30 at 1:00 AM | Brownstone Research (Ad)AnaptysBio Adjusts Fiscal Year-End and Reporting CalendarMay 21, 2026 | tipranks.comAnaptysBio (NASDAQ:ANAB) & Amgen (NASDAQ:AMGN) Head-To-Head SurveyMay 21, 2026 | americanbankingnews.comAnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 21, 2026 | americanbankingnews.comBarclays Remains a Buy on AnaptysBio (ANAB)May 15, 2026 | theglobeandmail.comAnaptys Announces First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | globenewswire.comSee More Headlines ANAB Stock Analysis - Frequently Asked Questions How have ANAB shares performed this year? AnaptysBio's stock was trading at $48.48 at the start of the year. Since then, ANAB stock has increased by 14.8% and is now trading at $55.67. How were AnaptysBio's earnings last quarter? AnaptysBio, Inc. (NASDAQ:ANAB) released its quarterly earnings results on Tuesday, May, 12th. The biotechnology company reported ($1.84) earnings per share for the quarter, missing the consensus estimate of ($0.64) by $1.20. The biotechnology company had revenue of $25.56 million for the quarter, compared to analysts' expectations of $18.86 million. AnaptysBio had a negative net margin of 11.53% and a negative trailing twelve-month return on equity of 1,101.24%. Is AnaptysBio buying back stock? AnaptysBio's Board of Directors initiated a stock repurchase plan on Friday, March 27th 2026, which permits the company to repurchase $100,000,000,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 5,352,316.2% of its stock through open market purchases. Stock buyback plans are typically an indication that the company's leadership believes its stock is undervalued. When did AnaptysBio IPO? AnaptysBio (ANAB) raised $75 million in an initial public offering on Thursday, January 26th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are AnaptysBio's major shareholders? AnaptysBio's top institutional shareholders include Affinity Asset Advisors LLC (3.23%), First Light Asset Management LLC (1.94%), Bank of America Corp DE (1.72%) and Arrowstreet Capital Limited Partnership (1.69%). Insiders that own company stock include Ecor1 Capital, Llc, Daniel Faga, Paul F Lizzul, John P Schmid, Dennis Mulroy, Eric J Loumeau, Magda Marquet, J Anthony Ware, Hollings Renton and Dennis M Fenton. View institutional ownership trends. How do I buy shares of AnaptysBio? Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AnaptysBio own? Based on aggregate information from My MarketBeat watchlists, some other companies that AnaptysBio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Moderna (MRNA) and Alphabet (GOOG). Company Calendar Last Earnings5/12/2026Today5/30/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (8m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ANAB's financial health is in the Green zone, according to TradeSmith. ANAB has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANAB CIK1370053 Webwww.anaptysbio.com Phone(858) 362-6295FaxN/AEmployees100Year Founded2005Price Target and Rating Average Price Target for AnaptysBio$79.18 High Price Target$100.00 Low Price Target$50.00 Potential Upside/Downside+42.2%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($1.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.23 million Net Margins-11.53% Pretax Margin-11.46% Return on Equity-1,101.24% Return on Assets-7.75% Debt Debt-to-Equity RatioN/A Current Ratio7.58 Quick Ratio7.58 Sales & Book Value Annual Sales$232.39 million Price / Sales6.97 Cash FlowN/A Price / Cash FlowN/A Book Value$0.44 per share Price / Book126.52Miscellaneous Outstanding Shares29,101,000Free Float19,352,000Market Cap$1.62 billion OptionableOptionable Beta0.79 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ANAB) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersMassive Data Leak Exposes 512,000-Line Code That Could Change Society Forever"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...Chaikin Analytics | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredI paid $5,000 to hear Elon say thisOne investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...InvestorPlace | SponsoredPresident Trump just sparked a stock market MELT UPThe real reason Musk, Huang, Cook, and Fink just flew to Beijing Last week, the CEOs of Nvidia, Apple, Spac...Stansberry Research | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe grid just blinked redOn May 4, 2026, NERC issued only the third Level 3 grid warning in history - the highest grade short of an act...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
